Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$3.62 -1.5%	$2.00	$1.05 ▼ $4.13	$358.53M	1.96	615,616 shs	829,699 shs
AQST Aquestive Therapeutics	$3.42 +3.3%	$2.76	$2.12 ▼ $5.80	$339.70M	1.94	1.54 million shs	1.22 million shs
CMPX Compass Therapeutics	$2.41	$2.00	$0.77 ▼ $4.08	$333.26M	1.41	952,012 shs	746,462 shs
JSPR Jasper Therapeutics	$5.58 +0.2%	$4.87	$3.13 ▼ $26.05	$83.82M	2.72	301,702 shs	151,017 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	-1.23%	-1.77%	+101.39%	+95.93%	+14.40%
AQST Aquestive Therapeutics	+3.32%	-3.93%	+54.05%	+20.42%	+21.71%
CMPX Compass Therapeutics	0.00%	-3.60%	+20.50%	-2.03%	+100.83%
JSPR Jasper Therapeutics	+0.18%	-7.15%	+15.05%	+1.64%	-76.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADCT ADC Therapeutics	2.6023 of 5 stars	3.5	3.0	3.2	0.8	0.6
AQST Aquestive Therapeutics	1.6912 of 5 stars	3.5	1.0	4.0	0.0	0.0
CMPX Compass Therapeutics	3.5716 of 5 stars	4.6	1.0	2.7	5.0	0.0
JSPR Jasper Therapeutics	2.785 of 5 stars	3.5	2.0	4.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	3.00	Buy	$8.50	135.13% Upside
AQST Aquestive Therapeutics	3.00	Buy	$10.14	196.57% Upside
CMPX Compass Therapeutics	3.11	Buy	$13.13	444.61% Upside
JSPR Jasper Therapeutics	3.00	Buy	$62.22	1,015.09% Upside

Current Analyst Ratings Breakdown

Latest JSPR, CMPX, ADCT, and AQST Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $10.00
6/2/2025	AQST Aquestive Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
5/15/2025	ADCT ADC Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$8.00 ➝ $8.00
5/15/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/15/2025	JSPR Jasper Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$80.00 ➝ $65.00
5/13/2025	JSPR Jasper Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $33.00
5/9/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
4/28/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/22/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/21/2025	CMPX Compass Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
4/21/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$75.82M	4.73	N/A	N/A	($1.93) per share	-1.87
AQST Aquestive Therapeutics	$54.23M	6.26	N/A	N/A	($1.59) per share	-2.15
CMPX Compass Therapeutics	$850K	392.07	N/A	N/A	$1.17 per share	2.06
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$7.03 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$240.05M	-$1.45	N/A	N/A	N/A	-300.00%	N/A	-61.33%	8/5/2025 (Estimated)
AQST Aquestive Therapeutics	-$7.87M	-$0.59	N/A	N/A	N/A	-59.75%	N/A	-33.96%	8/5/2025 (Estimated)
CMPX Compass Therapeutics	-$42.49M	-$0.41	N/A	N/A	N/A	N/A	-32.37%	-30.67%	8/11/2025 (Estimated)
JSPR Jasper Therapeutics	-$64.46M	-$5.24	N/A	N/A	N/A	N/A	-67.64%	-58.53%	8/12/2025 (Estimated)

Latest JSPR, CMPX, ADCT, and AQST Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ADCT ADC Therapeutics	-$0.38	-$0.36	+$0.02	-$0.36	$17.71 million	$23.03 million
5/12/2025	Q1 2025	AQST Aquestive Therapeutics	-$0.17	-$0.24	-$0.07	-$0.24	$12.23 million	$8.72 million
5/12/2025	Q1 2025	JSPR Jasper Therapeutics	-$1.17	-$1.41	-$0.24	-$1.41	N/A	N/A
5/8/2025	Q1 2025	CMPX Compass Therapeutics	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
3/27/2025	Q4 2024	ADCT ADC Therapeutics	-$0.35	-$0.29	+$0.06	-$0.29	$19.01 million	$19.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	4.92	4.68
AQST Aquestive Therapeutics	N/A	6.37	5.91
CMPX Compass Therapeutics	N/A	31.84	31.84
JSPR Jasper Therapeutics	N/A	7.61	7.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
AQST Aquestive Therapeutics	32.45%
CMPX Compass Therapeutics	68.43%
JSPR Jasper Therapeutics	79.85%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	4.10%
AQST Aquestive Therapeutics	8.35%
CMPX Compass Therapeutics	29.80%
JSPR Jasper Therapeutics	4.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	99.18 million	92.73 million	Optionable
AQST Aquestive Therapeutics	160	99.33 million	84.02 million	Optionable
CMPX Compass Therapeutics	20	138.28 million	98.38 million	Not Optionable
JSPR Jasper Therapeutics	20	15.02 million	14.60 million	Optionable

JSPR, CMPX, ADCT, and AQST Headlines

Recent News About These Companies

Cantor Fitzgerald Comments on JSPR FY2026 Earnings

June 11 at 2:23 AM | americanbankingnews.com

Analysts Offer Predictions for JSPR FY2026 Earnings

June 10, 2025 | marketbeat.com

Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress

June 3, 2025 | globenewswire.com

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Recommendation of "Buy" by Brokerages

June 1, 2025 | marketbeat.com

Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely

May 29, 2025 | finance.yahoo.com

Woodline Partners LP Decreases Stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

May 26, 2025 | marketbeat.com

Jasper Therapeutics, Inc. (JSPR): Analysts See 914% Upside Potential

May 21, 2025 | insidermonkey.com

Soleus Capital Management L.P. Has $31.95 Million Stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

May 21, 2025 | marketbeat.com

Jasper Therapeutics to Present at RBC and Jefferies Global Healthcare Conferences on Briquilimab Development

May 16, 2025 | nasdaq.com

Jasper Therapeutics (NASDAQ:JSPR) Releases Earnings Results, Misses Expectations By $0.24 EPS

May 14, 2025 | marketbeat.com

Jasper Therapeutics to Present at Upcoming Investor Conferences

May 14, 2025 | globenewswire.com

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Shares Acquired by Integral Health Asset Management LLC

May 14, 2025 | marketbeat.com

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025 | globenewswire.com

Why Jasper Therapeutics, Inc.’s (JSPR) Stock Is Down 5.34%

May 6, 2025 | aaii.com

Why Jasper Therapeutics, Inc.’s (JSPR) Stock Is Up 7.05%

April 22, 2025 | aaii.com

Why Jasper Therapeutics, Inc.’s (JSPR) Stock Is Up 7.55%

April 11, 2025 | aaii.com

Jasper Therapeutics inks new sales agreement, ends previous deal

March 21, 2025 | uk.investing.com

Jasper Therapeutics files $300M mixed securities shelf

March 19, 2025 | markets.businessinsider.com

Jasper Therapeutics presents updated data from Phase 1b/2a BEACON study

March 2, 2025 | msn.com

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

March 1, 2025 | globenewswire.com

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

February 28, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR, CMPX, ADCT, and AQST Company Descriptions

ADC Therapeutics NYSE:ADCT

$3.62 -0.06 (-1.50%)

Closing price 06/13/2025 03:59 PM Eastern

Extended Trading

$3.61 -0.01 (-0.14%)

As of 06/13/2025 07:47 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Aquestive Therapeutics NASDAQ:AQST

$3.42 +0.11 (+3.32%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$3.42 0.00 (0.00%)

As of 06/13/2025 07:57 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Compass Therapeutics NASDAQ:CMPX

$2.41 0.00 (0.00%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$2.42 +0.00 (+0.21%)

As of 06/13/2025 07:23 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Jasper Therapeutics NASDAQ:JSPR

$5.58 +0.01 (+0.18%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$5.56 -0.02 (-0.36%)

As of 06/13/2025 07:49 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time